ClinicalTrials.gg
CompletedNCT03351751Updated Jun 3, 2019

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in Healthy Subjects

A Phase 1 interventional study of Placebo and PF-06372865 in Healthy Volunteers, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-06-03.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Feb 2018, 8 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple repeat oral doses of PF-06372865 in healthy adult subjects.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • PF-06372865
  • Safety
  • Tolerability
  • Pharmacokinetics
  • Multiple dose
  • Healthy subjects
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy female subjects of non- and/or male subjects between the ages of 18 and 55 years
  2. of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb)
  3. Subjects who are willing and able to comply with all study procedures (including being able to swallow up to 8 tablets/dose or 16 tablets/day)
  4. For optional Japanese subjects only: Japanese subjects currently residing in the United States who have 4 biologic Japanese grandparents born in Japan

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease
  2. Subjects with history of sleep apnea
  3. Any condition possibly affecting drug absorption (eg, gastrectomy)
  4. Positive urine drug test
  5. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males
  6. Treatment with an drug within 30 days or 5 half-lives of the first dose of PF-06372865 (whichever is longer)
  7. Clinically significant orthostatic hypotension at screening or screening supine BP >=140 mm Hg (systolic) or >=90 mm Hg (diastolic), following at least 5 minutes of supine rest
  8. Screening supine 12-lead demonstrating a (QTc) interval >450 msec or a QRS interval >120 msec
  9. Subjects with any of the following abnormalities in clinical laboratory tests at screening: (AST) or alanine aminotransferase (ALT) level >=1.5x (ULN); total level >=1.5x ULN; subjects with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is \<=ULN
  10. Fertile male subjects who are unwilling or unable to use a highly effective method of for the duration of the study and for at least 60 days after the last dose of PF-06372865
  11. Male subjects whose partners are currently pregnant
  12. Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of PF-06372865
  13. Use of herbal supplements or hormone replacement therapy within 28 days prior to the first dose of PF-06372865
  14. Blood donation of approximately 1 pint (500 mL) or more within 60 days prior to dosing
  15. History of sensitivity to heparin or heparin-induced thrombocytopenia
  16. History of (HIV), , or ; positive testing for HIV, hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C antibody
  17. Other acute or chronic medical or psychiatric condition including recent or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or PF-06372865 administration or may interfere with the interpretation of study results
  18. Subjects with active suicidal ideations or suicidal behavior within 5 years prior to screening
  19. Subjects with history of cyclic neutropenia.
  20. Subjects with known history of to benzodiazepines, or for whom benzodiazepines would be
  21. Subjects who have previously been exposed to, or participated in a study with, PF-06372865
  22. Subjects with folate deficiency
  23. Subjects who have had an X-ray within 4 weeks prior to screening
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
19 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Subjects receiving placebo

    Drug: Placebo

  • Experimental
    PF-06372865

    Subjects receiving PF-06372865

    Drug: PF-06372865

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)

    Treatment-related AEs are any untoward medical occurrences attributed to study drug in a participant who received study drug. A serious adverse events (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28-35 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness to study drug is assessed by the investigator. Participants with multiple occurrences of an AE within a category are counted once within the category.

    Time frame: Baseline up to 28-35 days after last dose of study medication

  2. Change From Baseline in Vital Signs

    Measurement of systolic and diastolic blood pressure and pulse rate

    Time frame: 0, 1, 2, 4, 8, and 12 hours post-dose on Days 1 and 21; also 0 and 2 hours post-dose on Days 4, 8, 11, 14, and 17

  3. Change From Baseline in Electrocardiogram (ECG) Parameters

    Measurement of the following ECG parameters: QT interval, QTcF, PR interval, RR interval, QRS interval, and heart rate.

    Time frame: 0, 1, 2, 4, 8, and 12 hours post-dose on Days 1 and 21; also 0 and 2 hours post-dose on Days 4, 8, 11, 14, and 17

  4. Number of Participants With Clinical Laboratory Abnormalities

    Lab tests include: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); blood chemistry (blood urea nitrogen, creatinine, glucose, calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid albumin, total protein, folate); urinalysis (decimal logarithm of reciprocal of hydrogen ion activity \[pH\], glucose, protein, blood, ketones, nitrites, leukocyte esterase, urobilinogen, urine bilirubin, microscopy); other (follicle stimulating hormone, urine drug screening, hepatitis B surface antigen, hepatitis B core antibody, hepatitis C antibody, human immunodeficiency virus).

    Time frame: Baseline up to 7-10 days after last dose of study medication

  5. Maximum Observed Plasma Concentration (Cmax) for PF-06372865 on Day 1

    Maximum observed plasma concentration

    Time frame: 0, 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours post-dose

  6. Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06372865 on Day 1

    Time to reach maximum observed plasma concentration

    Time frame: 0, 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours post-dose

  7. Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for PF-06372865 on Day 1

    Area under the concentration curve from time 0 to end of the dosing interval. The dosing interval is 12 hours.

    Time frame: 0, 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours post-dose

  8. Maximum Observed Plasma Concentration (Cmax) for PF-06372865 on Day 21

    Maximum observed plasma concentration

    Time frame: 0, 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours post-dose

  9. Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06372865 on Day 21

    Time to reach maximum observed plasma concentration

    Time frame: 0, 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours post-dose

  10. Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) for PF-06372865 on Day 21

    Area under the concentration curve from time 0 to end of the dosing interval. The dosing interval is 12 hours.

    Time frame: 0, 0.5, 1, 1.5, 2, 4, 6, 8, and 12 hours post-dose

  11. Plasma Half-Life (t1/2)

    Time for the plasma concentration to decrease by one half.

    Time frame: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, and 72 hours post-dose on Day 21

07

Study locations

1 site
  • Pfizer New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Feb 2018, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2017
First posted
Nov 24, 2017
StartActual
Nov 8, 2017
Primary completionActual
Feb 28, 2018
CompletionActual
Feb 28, 2018
Last update
Jun 3, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03351751
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 24, 2017
Start date
Nov 8, 2017
Primary completion
Feb 28, 2018
Completion
Feb 28, 2018
Last update
Jun 3, 2019

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06372865

Start the discussion